These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20378569)

  • 21. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
    Dasmahapatra G; Lembersky D; Rahmani M; Kramer L; Friedberg J; Fisher RI; Dent P; Grant S
    Cancer Biol Ther; 2009 May; 8(9):808-19. PubMed ID: 19270531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
    Gu H; Chen X; Gao G; Dong H
    Mol Cancer Ther; 2008 Aug; 7(8):2298-307. PubMed ID: 18723477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.
    Jantus-Lewintre E; Sarsotti E; Terol MJ; Benet I; García-Conde J
    Clin Transl Oncol; 2006 Nov; 8(11):805-11. PubMed ID: 17134969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
    Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
    Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
    Ling YH; Liebes L; Zou Y; Perez-Soler R
    J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
    Ruiz S; Krupnik Y; Keating M; Chandra J; Palladino M; McConkey D
    Mol Cancer Ther; 2006 Jul; 5(7):1836-43. PubMed ID: 16891470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
    Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S; Boise LH; Lee KP; Nikiforov MA
    Blood; 2012 Feb; 119(6):1450-8. PubMed ID: 22144178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
    Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
    Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
    Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
    Yu C; Rahmani M; Dent P; Grant S
    Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
    Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
    Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa.
    Zaher M; Tang R; Bombarda I; Merhi F; Bauvois B; Billard C
    Int J Oncol; 2012 Jan; 40(1):269-76. PubMed ID: 21947285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
    Wirth M; Stojanovic N; Christian J; Paul MC; Stauber RH; Schmid RM; Häcker G; Krämer OH; Saur D; Schneider G
    Nucleic Acids Res; 2014; 42(16):10433-47. PubMed ID: 25147211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
    Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
    Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
    Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.